Ann: Quarterly Report and Appendix 4C, page-8

MDR is being priced as MedAdvisor and not MedAdvisor with Adheris.

Anyone buying before the June quarter results is extremely brave.

There's a number of announcements to get through that might steady the ship:

• Replacement CEO. They are targeting a US based Exec.
  • What calibre resource will they get to manage an ASX listed healthcare stock?

• Final earn-out to Syneos in September.
  • How will this be funded? Cash, CR, PFG?

• Any and I mean any price sensitive news that confirms an extension to or new revenue stream.
  • It's all well and good to simply publish quarterlies, if you're meeting your revenue targets.

Better numbers in June is needed, else they will require a number of quarters to regain trust.